Obesity-related changes in high-density lipoprotein metabolism.

Department of Medicine, University of Florida College of Medicine, Jacksonville, Florida, USA.
Obesity (Impact Factor: 4.39). 07/2008; 16(6):1152-60. DOI: 10.1038/oby.2008.202
Source: PubMed

ABSTRACT Obesity is associated with a 3-or-more-fold increase in the risk of fatal and nonfatal myocardial infarction (1,2,3,4,5,6). The American Heart Association has reclassified obesity as a major, modifiable risk factor for coronary heart disease (7). The increased prevalence of premature coronary heart disease in obesity is attributed to multiple factors (8,9,10). A principal contributor to this serious morbidity is the alterations in plasma lipid and lipoprotein levels. The dyslipidemia of obesity is commonly manifested as high plasma triglyceride levels, low high-density lipoprotein cholesterol (HDLc), and normal low-density lipoprotein cholesterol (LDLc) with preponderance of small dense LDL particles (7,8,9,10). However, there is a considerable heterogeneity of plasma lipid profile in overweight and obese people. The precise cause of this heterogeneity is not entirely clear but has been partly attributed to the degree of visceral adiposity and insulin resistance. The emergence of glucose intolerance or a genetic predisposition to familial combined hyperlipidemia will further modify the plasma lipid phenotype in obese people (11,12,13,14,15).

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BackgroundWe aimed to comprehensively evaluate lipoprotein profile including lipid particle size following a lifestyle intervention in metabolic syndrome (MetS) volunteers and to assess the associations between lipoprotein subfractions and carotid-intima-media-thickness (CIMT) – a surrogate indicator of atherogenesis.Methods100 participants (50–70 years) from the RESOLVE trial, underwent a one-year follow-up beginning with a three-week residential program combining high exercise volume (15-20 h/week), restrictive diet (-500 kcal/day), and education. For baseline references, 40 aged-matched healthy controls were recruited. Independent associations between subfractions of lipoproteins and CIMT were evaluated using a generalized estimating equations model accounting for variation in correlations between repeated measures. The lipoprotein subfractions profile was assessed using Lipoprint® electrophoresis allowing to separate: the very low-density lipoprotein (VLDL) fraction, then the intermediate-density lipoprotein (IDL) C, B and A, the low-density lipoprotein (LDL) with subfractions 1 and 2 as large LDL and subfractions 3 to 7 as small dense LDL (sdLDL), and the high density lipoprotein (HDL) subfractions categorized into large, intermediate, and small HDL. Apolipoproteins A1 and B were also measured.Results78 participants completed the program. At baseline, apolipoproteins B/A1, VLDL, sdLDL and small HDL were higher in MetS than in healthy controls; IDL, LDL size, large and intermediate HDL were lower. Despite time-related regains during the follow-up, lipoprotein subfractions traditionally involved in cardiovascular risk, such as sdLDL, improved immediately after the residential program with values closest to those of healthy controls. CIMT improved throughout the lifestyle intervention. Using a generalized estimating equations model, none of the subfractions of lipoproteins nor apolipoproteins were linked to CIMT.ConclusionsLipoprotein subfractions traditionally involved in CVR, decreased after the 3-week residential program. During a 12 month follow-up, the time-related regains remained closer to the values of healthy controls than they were at baseline. CIMT improved throughout the lifestyle intervention. However, we failed to demonstrate a link between some lipoprotein subfractions and the atherogenicity directly measured from the wall thickness of arteries (CIMT). Further investigations are required to explore the atherogenicity of lipoprotein subfractions.Trial registrationNCT00917917
    Lipids in Health and Disease 07/2014; 13(1). DOI:10.1186/1476-511X-13-112 · 2.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Evaluate the effect of dietetic WHO's recommendations on hypoHDLemia in obese Tunisians volunteers.Methods We enrolled 93 volunteers hospital personal. Anthropometric parameters, blood pressure, lipids levels, glycemia and insulinemia were measured. Dietary intake assessment was undertaken, results were transformed into dichotomic variables according to the respect or not of the WHO's recommendations for chronic diseases prevention. Health Diet Index (HDI) was calculated.ResultsAfter adjustment for potential confounders factors, we found significant reduction of hypoHDLemia risk by respect of the dietetic WHO's recommendations for the saturated fatty acids (OR = 0.602; P = 0.033), monounsaturated fatty acids (OR = 0.765; P = 0.038), fish consumption (OR = 0.633; P = 0.049) free sugar (OR = 0.759; P = 0.041). OR of hypoHDLemia associated with a HDI greater than or equal to 4 was 0.218; P = 0.048. These same recommendations have significant effect to reduce high TC/HDL-C. In addition PUFA [6–10%], total carbohydrates [55–75%] and increased fruits and vegetables protect against high TC/HDL-C.Conclusion Several dietetic WHO's recommendations seem to prevent hypoHDLemia. The association of at least four recommendations had a significant beneficial effect.
    Immuno-analyse & Biologie Spécialisée 06/2012; 27(3):97-103. DOI:10.1016/j.immbio.2012.02.006 · 0.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Inflammation is a fundamental feature of several complex cardiometabolic diseases. Indeed, obesity, insulin resistance, metabolic dyslipidemia, and atherosclerosis are all closely linked inflammatory states. Increasing evidence suggests that the infectious, biome-related, or endogenous activation of the innate immune system may contribute to the development of metabolic syndrome and cardiovascular disease. Here, we describe the human experimental endotoxemia model for the specific study of innate immunity in understanding further the pathogenesis of cardiometabolic disease. In a controlled, experimental setting, administration of an intravenous bolus of purified Escherichia coli endotoxin activates innate immunity in healthy human volunteers. During endotoxemia, changes emerge in glucose metabolism, lipoprotein composition, and lipoprotein functions that closely resemble those observed chronically in inflammatory cardiovascular disease risk states. In this review, we describe the transient systemic inflammation and specific metabolic consequences that develop during human endotoxemia. Such a model provides a controlled induction of systemic inflammation, eliminates confounding, undermines reverse causation, and possesses unique potential as a starting point for genomic screening and testing of novel therapeutics for treatment of the inflammatory underpinning of cardiometabolic disease. © 2014 American Heart Association, Inc.
    Arteriosclerosis Thrombosis and Vascular Biology 12/2014; 35(3). DOI:10.1161/ATVBAHA.114.304455 · 5.53 Impact Factor


1 Download